Often rare diseases are chronic and life-threatening. Rare diseases can be single gene, multifactorial, chromosomal or non-genetic.
Highlights
The global Rare Disease Diagnostics market was valued at US$ 22460 million in 2022 and is anticipated to reach US$ 36260 million by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rare Disease Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Rare Disease Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Rare Disease Diagnostics in Hospital Laboratories is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Rare Disease Diagnostics include Retrophin, 3billion, 23andMe, QIAGEN, Illumina, PerkinElmer and Strand Life Sciences, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rare Disease Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare Disease Diagnostics.
The Rare Disease Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Rare Disease Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rare Disease Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Retrophin
3billion
23andMe
QIAGEN
Illumina
PerkinElmer
Strand Life Sciences
Segment by Type
Hematology
Oncology
Segment by Application
Hospital Laboratories
Diagnostic Laboratories
Genetic Testing Laboratories
Cancer Research Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rare Disease Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Rare Disease Diagnostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hematology
1.2.3 Oncology
1.3 麻豆原创 by Application
1.3.1 Global Rare Disease Diagnostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Laboratories
1.3.3 Diagnostic Laboratories
1.3.4 Genetic Testing Laboratories
1.3.5 Cancer Research Laboratories
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rare Disease Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 Rare Disease Diagnostics Growth Trends by Region
2.2.1 Global Rare Disease Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Rare Disease Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Rare Disease Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Rare Disease Diagnostics 麻豆原创 Dynamics
2.3.1 Rare Disease Diagnostics Industry Trends
2.3.2 Rare Disease Diagnostics 麻豆原创 Drivers
2.3.3 Rare Disease Diagnostics 麻豆原创 Challenges
2.3.4 Rare Disease Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rare Disease Diagnostics Players by Revenue
3.1.1 Global Top Rare Disease Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Rare Disease Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Rare Disease Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rare Disease Diagnostics Revenue
3.4 Global Rare Disease Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Rare Disease Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rare Disease Diagnostics Revenue in 2022
3.5 Rare Disease Diagnostics Key Players Head office and Area Served
3.6 Key Players Rare Disease Diagnostics Product Solution and Service
3.7 Date of Enter into Rare Disease Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Rare Disease Diagnostics Breakdown Data by Type
4.1 Global Rare Disease Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Rare Disease Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Rare Disease Diagnostics Breakdown Data by Application
5.1 Global Rare Disease Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Rare Disease Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Rare Disease Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America Rare Disease Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Rare Disease Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4 North America Rare Disease Diagnostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rare Disease Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe Rare Disease Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Rare Disease Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Rare Disease Diagnostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rare Disease Diagnostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Rare Disease Diagnostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Rare Disease Diagnostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Rare Disease Diagnostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rare Disease Diagnostics 麻豆原创 Size (2018-2029)
9.2 Latin America Rare Disease Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Rare Disease Diagnostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Rare Disease Diagnostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rare Disease Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Rare Disease Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Rare Disease Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Rare Disease Diagnostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Retrophin
11.1.1 Retrophin Company Detail
11.1.2 Retrophin Business Overview
11.1.3 Retrophin Rare Disease Diagnostics Introduction
11.1.4 Retrophin Revenue in Rare Disease Diagnostics Business (2018-2023)
11.1.5 Retrophin Recent Development
11.2 3billion
11.2.1 3billion Company Detail
11.2.2 3billion Business Overview
11.2.3 3billion Rare Disease Diagnostics Introduction
11.2.4 3billion Revenue in Rare Disease Diagnostics Business (2018-2023)
11.2.5 3billion Recent Development
11.3 23andMe
11.3.1 23andMe Company Detail
11.3.2 23andMe Business Overview
11.3.3 23andMe Rare Disease Diagnostics Introduction
11.3.4 23andMe Revenue in Rare Disease Diagnostics Business (2018-2023)
11.3.5 23andMe Recent Development
11.4 QIAGEN
11.4.1 QIAGEN Company Detail
11.4.2 QIAGEN Business Overview
11.4.3 QIAGEN Rare Disease Diagnostics Introduction
11.4.4 QIAGEN Revenue in Rare Disease Diagnostics Business (2018-2023)
11.4.5 QIAGEN Recent Development
11.5 Illumina
11.5.1 Illumina Company Detail
11.5.2 Illumina Business Overview
11.5.3 Illumina Rare Disease Diagnostics Introduction
11.5.4 Illumina Revenue in Rare Disease Diagnostics Business (2018-2023)
11.5.5 Illumina Recent Development
11.6 PerkinElmer
11.6.1 PerkinElmer Company Detail
11.6.2 PerkinElmer Business Overview
11.6.3 PerkinElmer Rare Disease Diagnostics Introduction
11.6.4 PerkinElmer Revenue in Rare Disease Diagnostics Business (2018-2023)
11.6.5 PerkinElmer Recent Development
11.7 Strand Life Sciences
11.7.1 Strand Life Sciences Company Detail
11.7.2 Strand Life Sciences Business Overview
11.7.3 Strand Life Sciences Rare Disease Diagnostics Introduction
11.7.4 Strand Life Sciences Revenue in Rare Disease Diagnostics Business (2018-2023)
11.7.5 Strand Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Retrophin
3billion
23andMe
QIAGEN
Illumina
PerkinElmer
Strand Life Sciences
听
听
*If Applicable.
